Cytokinetics (CYTK) and Its Rivals Head to Head Survey

Cytokinetics (NASDAQ:CYTK) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Cytokinetics to related companies based on the strength of its profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Cytokinetics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-686.63%	N/A	-48.26%
Cytokinetics Competitors	-12,346.73%	-197.60%	-30.56%

Valuation and Earnings

This table compares Cytokinetics and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Cytokinetics	$113.29 million	-$784.96 million	-8.89
Cytokinetics Competitors	$720.93 million	$13.04 million	-15.10

Cytokinetics’ rivals have higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional and Insider Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Cytokinetics and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	19	0	2.86
Cytokinetics Competitors	9839	15124	45438	1588	2.54

Cytokinetics currently has a consensus target price of $106.67, indicating a potential upside of 98.67%. As a group, “Biotechnology” companies have a potential upside of 103.10%. Given Cytokinetics’ rivals higher probable upside, analysts clearly believe Cytokinetics has less favorable growth aspects than its rivals.

Volatility and Risk

Cytokinetics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Cytokinetics’ rivals have a beta of 1.10, meaning that their average stock price is 10% more volatile than the S&P 500.

Summary

Cytokinetics rivals beat Cytokinetics on 8 of the 13 factors compared.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.